Research programme: enzyme inhibitors - Arresto Biosciences
Alternative Names: AB 0023Latest Information Update: 28 Aug 2012
At a glance
- Originator Arresto Biosciences
- Class Monoclonal antibodies
- Mechanism of Action Growth factor receptor antagonists; LOXL2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation; Pulmonary fibrosis
Most Recent Events
- 28 Aug 2012 No development reported - Preclinical for Cancer in USA (Parenteral)
- 28 Aug 2012 No development reported - Preclinical for Inflammation in USA (Parenteral)
- 28 Aug 2012 No development reported - Preclinical for Pulmonary fibrosis in USA (Parenteral)